Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G, Chatzis O, Chinwangso P, Rohr M, Grillet S, Salomon C, Lemaître B, Boonrak P, Lawpoolsri S, Clutterbuck E, Poredi IK, Wijagkanalan W, Spiegel J, Pham HT, Viviani S, Siegrist CA. Blanchard Rohner G, et al. Among authors: viviani s. Clin Infect Dis. 2019 Mar 19;68(7):1213-1222. doi: 10.1093/cid/ciy594. Clin Infect Dis. 2019. PMID: 30759183 Clinical Trial.
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C, Chanthavanich P, Limkittikul K, Siegrist CA, Wijagkanalan W, Chinwangso P, Petre J, Hong Thai P, Chauhan M, Viviani S. Sirivichayakul C, et al. Among authors: viviani s. Hum Vaccin Immunother. 2017 Jan 2;13(1):136-143. doi: 10.1080/21645515.2016.1234555. Epub 2016 Sep 29. Hum Vaccin Immunother. 2017. PMID: 27686283 Free PMC article. Clinical Trial.
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S, Sirivichayakul C, Chokephaibulkit K, Pitisuttithum P, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chinwangso P, Poredi IK, Petre J, Thai PH, Viviani S. Sricharoenchai S, et al. Among authors: viviani s. Lancet Infect Dis. 2018 Jan;18(1):58-67. doi: 10.1016/S1473-3099(17)30612-6. Epub 2017 Oct 20. Lancet Infect Dis. 2018. PMID: 29066131 Clinical Trial.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani S. Pitisuttithum P, et al. Among authors: viviani s. Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25. Lancet Infect Dis. 2018. PMID: 30266329 Clinical Trial.
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
Chokephaibulkit K, Puthanakit T, Bhat N, Mansouri S, Tang Y, Lapphra K, Rungmaitree S, Anugulruengkitt S, Jantarabenjakul W, Andi-Lolo I, Holt R, Fortuna L, Kerdsomboon C, Chinwangso P, Suwitruengrit L, van den Biggelaar AHJ, Viviani S, Pham HT, Innis BL. Chokephaibulkit K, et al. Among authors: viviani s. Vaccine. 2022 Apr 1;40(15):2352-2361. doi: 10.1016/j.vaccine.2021.10.076. Epub 2021 Nov 14. Vaccine. 2022. PMID: 34789403 Free PMC article. Clinical Trial.
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.
Pitisuttithum P, Dhitavat J, Sirivichayakul C, Pitisuthitham A, Sabmee Y, Chinwangso P, Kerdsomboon C, Fortuna L, Spiegel J, Chauhan M, Poredi IK, van den Biggelaar AHJ, Wijagkanalan W, Viviani S, Mansouri S, Pham HT. Pitisuttithum P, et al. Among authors: viviani s. EClinicalMedicine. 2021 Jun 23;37:100976. doi: 10.1016/j.eclinm.2021.100976. eCollection 2021 Jul. EClinicalMedicine. 2021. PMID: 34386749 Free PMC article.
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A, Sow SO, Idoko OT, Hirve S, Findlow H, Preziosi MP, Elie C, Kulkarni PS, Parulekar V, Diarra B, Cheick Haidara F, Diallo F, Tapia M, Akinsola AK, Adegbola RA, Bavdekar A, Juvekar S, Chaumont J, Martellet L, Marchetti E, LaForce MF, Plikaytis BD, Enwere GC, Tang Y, Borrow R, Carlone G, Viviani S. Diallo A, et al. Among authors: viviani s. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S521-30. doi: 10.1093/cid/civ518. Clin Infect Dis. 2015. PMID: 26553684 Free PMC article. Clinical Trial.
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
Withanage K, De Coster I, Cools N, Viviani S, Tourneur J, Chevandier M, Lambiel M, Willems P, Le Vert A, Nicolas F, Van Damme P. Withanage K, et al. Among authors: viviani s. J Infect Dis. 2022 Aug 12;226(1):119-127. doi: 10.1093/infdis/jiab532. J Infect Dis. 2022. PMID: 34653245 Free PMC article. Clinical Trial.
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Tapia MD, Findlow H, Idoko OT, Preziosi MP, Kulkarni PS, Enwere GC, Elie C, Parulekar V, Sow SO, Haidara FC, Diallo F, Doumbia M, Akinsola AK, Adegbola RA, Kampmann B, Chaumont J, Martellet L, Marchetti E, Viviani S, Tang Y, Plikaytis BD, LaForce FM, Carlone G, Borrow R. Tapia MD, et al. Among authors: viviani s. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S514-20. doi: 10.1093/cid/civ672. Clin Infect Dis. 2015. PMID: 26553683 Free PMC article. Clinical Trial.
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. Sabchareon A, et al. Among authors: viviani s. Lancet. 2012 Nov 3;380(9853):1559-67. doi: 10.1016/S0140-6736(12)61428-7. Epub 2012 Sep 11. Lancet. 2012. PMID: 22975340 Clinical Trial.
185 results